Documentary on Holmes Highlights Lingering Regulatory Void in Laboratory Testing

A documentary about Elizabeth Holmes debuted without warning at the Telluride Film Festival, refocusing public attention on a company whose core failure extended beyond Holmes’s fraud conviction. She was convicted in January 2022 on four counts of investor fraud. The patients who received faulty blood‑test results were never prosecuted.

You Can See Everything, directed by Nathan Fielder and Lance Oppenheim, is a 174‑minute film that tracks Holmes from 34 days before her federal prison term through three subsequent years. A24 announced an October theatrical release, coinciding with the festival surprise screening. Holmes’s conviction for investor fraud came in January 2022, and she was sentenced to more than 11 years that November.

Most media coverage stops at the investor‑fraud conviction, but the patient‑harm dimension—how faulty tests affected real people—remains the critical, under‑reported issue for anyone undergoing blood testing.

The Numbers Behind the Patient Side

Theranos voided or corrected tens of thousands of blood‑test results. Its own laboratory director later testified that he nullified every test run on the company’s Edison devices during 2014‑2015, informing Holmes that the instruments had never functioned correctly.

Arizona offers the most complete accounting, thanks to its attorney general’s investigation. From 2013 to 2016, Theranos sold about 1.5 million blood tests to more than 175,000 Arizona residents via a Walgreens partnership. Roughly 10.5 % of those tests were voided or corrected. The company settled for $4.65 million in customer refunds, $200,000 in civil penalties, and $25,000 in legal fees, with refunds guaranteed to all Arizona customers regardless of whether their individual results were altered. Theranos acknowledged no fault and denied misrepresenting its technology’s accuracy.

Federal inspectors first examined Theranos’s California lab. A November 2015 survey revealed conditions that CMS described in a January 2016 letter as posing an “immediate jeopardy” to patient safety, with deficiencies across five CLIA requirements. The subsequent inspection report showed Edison device quality‑control checks that violated the company’s own protocols, testing performed by unqualified staff, and a failure to inform patients and physicians of flawed results. A later inspection of the Arizona lab uncovered comparable notification lapses for diabetes‑related tests and misconfigured blood‑coagulation assays.

The federal enforcement action resulted in a $30,000 civil monetary penalty. As part of the settlement, CMS withdrew its revocation of Theranos’s laboratory certification, Theranos dismissed its appeals, and the company pledged not to own or operate a laboratory for two years.

The Regulatory Question That Is Still Open

Theranos functioned as a clinical laboratory that developed and performed its own tests—known as laboratory‑developed tests (LDTs). Historically, LDTs have been regulated by CMS under the Clinical Laboratory Improvement Amendments (CLIA) rather than undergoing pre‑market review by the FDA.

CLIA audits laboratories for procedural and quality‑control standards but does not mandate that a lab prove a new test accurately measures its intended analyte before patient use. This regulatory gap enables unvalidated tests to reach the public—a loophole that predated Theranos and is not unique to the company.

The FDA sought to close the gap by issuing a May 2024 rule that would have classified LDTs as medical devices, with a four‑year phase‑in period. On March 31 2025, a federal court in the Eastern District of Texas voided the rule entirely, ruling that the agency lacks statutory authority because such tests constitute professional services, not manufactured devices. The court remanded the matter to the FDA, and a Congressional Research Service summary reflects the decision.

The FDA declined to appeal. In September 2025 it finalized the rescission of the rule, reinstating the prior regulatory framework and returning oversight to CMS under CLIA, exactly as it existed before the Theranos case.

Competing Views on Whether That Is a Problem

Experts hold divergent views on whether the ongoing gap constitutes a problem, and the debate should be presented without oversimplification. Laboratory and pathology groups warned that the vacated rule would have imposed substantial costs, delayed development of rare‑disease tests, and created redundant oversight already covered by CLIA. In its post‑ruling statement, the American Clinical Laboratory Association argued that the decision safeguards patient access to essential testing services.

Patient‑safety advocates and the FDA countered that CLIA evaluates laboratory processes but does not verify the analytical validity of individual tests, and that modern testing—especially genetic and oncology assays—has become far too complex for a framework originally written in 1988.

The court resolved only the legal question of the FDA’s authority, leaving unresolved whether the oversight gap poses a public‑health risk. Addressing the issue would now require congressional action, but no such legislation has been enacted.

Reasonable Steps for Patients Getting Blood Work

The vast majority of laboratory testing in the United States remains reliable, and this history should not deter patients from undergoing blood work recommended by their clinicians. For any given individual, the actual risk is more limited than the overall saga suggests.

The concern is most acute with direct‑to‑consumer testing, where patients order assays without clinician oversight. A sensible question is whether the test has undergone FDA review or is offered as a laboratory‑developed test; a company’s inability to provide a clear answer is a red flag. Any result that would drive a major health decision should be corroborated by an independent laboratory before action is taken.

When confronted with an unexpected result, the most effective first step is often the simplest: discuss the finding with the ordering clinician to determine whether it aligns with the patient’s clinical picture and whether a repeat test is advisable—especially before making any significant health decisions.

The film opens in theaters in October. The regulatory question it highlights—whether LDTs should be subject to FDA oversight—has remained unresolved since the CLIA framework was established in 1988.

Key Questions Answered

What was Elizabeth Holmes actually convicted of? Holmes was convicted in January 2022 of four counts of investor fraud; she was not convicted of any charges related to patient harm from inaccurate test results.

How many patients were affected? The company voided or corrected tens of thousands of patient test results. In Arizona alone, about 10.5 % of roughly 1.5 million tests sold to over 175,000 residents were altered.

What penalties did the company face for the laboratory failures? Theranos incurred a $30,000 civil penalty from CMS and a $4.65 million settlement with the Arizona attorney general, which required refunds to all Arizona customers.

What is a laboratory developed test? A laboratory‑developed test (LDT) is an assay designed and performed within a clinical laboratory itself, historically regulated by CMS under CLIA without prior FDA review.

Did regulators close the oversight gap after Theranos? Regulators have not closed the gap. An FDA rule intended to govern LDTs was vacated by a federal court in March 2025 and officially rescinded by the agency in September 2025.

Is routine blood work safe? Routine blood work remains generally safe; the broader Theranos history does not justify avoiding clinically ordered tests.

What should someone do about an unexpected result? If a patient receives an unexpected result, the first step is to discuss it with the ordering clinician—to assess whether the finding aligns with the clinical context and whether a repeat test is advisable—especially before making any significant health decisions.

Source link